During the last session, AnaptysBio Inc (NASDAQ:ANAB)’s traded shares were 0.34 million, with the beta value of the company hitting -0.20. At the end of the trading day, the stock’s price was $26.2, reflecting an intraday gain of 0.42% or $0.11. The 52-week high for the ANAB share is $41.31, that puts it down -57.67 from that peak though still a striking 53.4% gain since the share price plummeted to a 52-week low of $12.21. The company’s market capitalization is $769.77M, and the average intraday trading volume over the past 10 days was 0.56 million shares, and the average trade volume was 621.18K shares over the past three months.
AnaptysBio Inc (ANAB) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.33. ANAB has a Sell rating from 0 analyst(s) out of 6 analysts who have looked at this stock. 3 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -1.55.
AnaptysBio Inc (NASDAQ:ANAB) trade information
AnaptysBio Inc (ANAB) registered a 0.42% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 0.42% in intraday trading to $26.2, hitting a weekly high. The stock’s 5-day price performance is 10.32%, and it has moved by 9.30% in 30 days. Based on these gigs, the overall price performance for the year is 97.89%. The short interest in AnaptysBio Inc (NASDAQ:ANAB) is 9.15 million shares and it means that shorts have 12.72 day(s) to cover.
The consensus price target of analysts on Wall Street is $39.5, which implies an increase of 33.67% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $25 and $54 respectively. As a result, ANAB is trading at a discount of -106.11% off the target high and 4.58% off the low.
AnaptysBio Inc (ANAB) estimates and forecasts
In the rating firms’ projections, revenue will decrease -12.98% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 11.68M as predicted by 11 analyst(s). Meanwhile, a consensus of 11 analyst(s) estimates revenue growth to 11.76M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 10.97M and 30.02M respectively. In this case, analysts expect current quarter sales to grow by 6.50% and then drop by -60.81% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -7.30%. While earnings are projected to return -2.88% in 2025, the next five years will return -2.22% per annum.
ANAB Dividends
AnaptysBio Inc is due to release its next quarterly earnings on 2025-May-05. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
AnaptysBio Inc (NASDAQ:ANAB)’s Major holders
AnaptysBio Inc insiders own 5.10% of total outstanding shares while institutional holders control 134.20%, with the float percentage being 141.42%. ECOR1 CAPITAL, LLC is the largest shareholder of the company, while 212.0 institutions own stock in it. As of 2024-06-30, the company held over 7.52 million shares (or 27.4931% of all shares), a total value of $188.48 million in shares.
The next largest institutional holding, with 2.87 million shares, is of FMR LLC’s that is approximately 10.4936% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $71.94 million.
Also, the Mutual Funds coming in first place with the largest holdings of AnaptysBio Inc (ANAB) shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and T. Rowe Price New Horizons Fund, Inc. . Data provided on Mar 31, 2025 indicates that VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund owns about 668.95 shares. This amounts to just over 2.28 percent of the company’s overall shares, with a $17.53 million market value. The same data shows that the other fund manager holds slightly less at 545.28, or about 1.86% of the stock, which is worth about $14.29 million.
